← All trials
NCT04275518
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2020
- Primary completion
- Mar 20, 2022
- Completion date
- Aug 20, 2022
- First posted
- Feb 19, 2020
- Last posted
- Feb 25, 2020
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ascentage Pharma Group Inc.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.